SAN ANTONIO, October 08, 2026--bioAffinity Technologies receives notice of allowance for new patent in Japan covering its noninvasive CyPath Lung diagnostic test for lung cancer.

Human breath could help identify cancerous lung nodules and reduce the need for invasive testing. New Griffith University research analyzed exhaled breath to help doctors distinguish between cancerous ...

Office-based pulmonary function testing, also known as spirometry, is a powerful tool for primary care physicians to diagnose and manage respiratory problems. An obstructive defect is indicated by a ...

The number of ordering physicians increased by 89% in Q3 2026 compared to Q3 2025. Physicians who ordered CyPath Lung through Q3 2025 continued to expand utilization of the test, with sales volume ...

Cizzle Bio is moving its CIZ1B lung cancer blood test into commercial use in the US, with recent clinical research supporting ...

SAN ANTONIO, Texas, February 17, 2026--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung ...

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit ...

UVA Health researchers have discovered a potential way to predict which patients with severe COVID-19 are likely to recover well and which are likely to suffer "long-haul" lung problems. That finding ...

Race-correction for spirometry, a type of pulmonary function test, is commonly done in medical institutions across the United States. Recently, the American Thoracic Society released recommendations ...